Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

<p>An undisclosed shareholder of MISC is selling USD 119 million block of the company after market close today. In our insight, we will briefly look at the fundamentals and exposure of the company, shortlist the potential sellers of the deal, and score the deal in our ECM Framework. </p>

An undisclosed shareholder of MISC is selling USD 119 million block of the company after market close today. In our insight, we will briefly look at the fundamentals and exposure of the company, shortlist the potential sellers of the deal, and score the deal in our ECM Framework. 

MISC Placement: An Opportunistic Sell-Down when Geopolitical Risks Are Priced-In

Misc Bhd

MISC Placement: An Opportunistic Sell-Down when Geopolitical Risks Are Priced-In